Механизмы Действия Ритуксимаба

Гильдеева, Г. Н.; Кудлай, Д. А.; Лукьянов, С. В.

doi:10.30906/0869-2092-2015-78-12-51-56

Эксп. и клин. фармакол.

2015

DOI: 10.30906/0869-2092-2015-78-12-51-56

|View full text |Cite

Механизмы Действия Ритуксимаба

Г. Н. Гильдеева¹,

Д. А. Кудлай²,

С. В. Лукьянов³

Abstract: Ðèòóêñèìàá -õèìåðíîå ìîíîêëîíàëüíîå àíòèòåëî, âêëþ÷àþùåå êàïïà (k)-êîíñòàí-òíûå ðåãèîíû Fc-ôðàãìåíòà èììóíîãëîáóëèíà IgG1 ÷åëîâåêà è âàðèàáåëüíûå ôðàã-ìåíòû èììóíîãëîáóëèíà IgG1 ìûøè. Òàêàÿ ìîäèôèöèðîâàííàÿ ñòðóêòóðà èììóíîãëî-áóëèíà íàäåëÿåò ðèòóêñèìàá ñïîñîáíîñòüþ ñïåöèôè÷åñêè ðàñïîçíàâàòü àíòèãåí CD20, ýêñïîíèðóåìûé, ãëàâíûì îáðàçîì, íà Â-ëèìôîöèòàõ. Â îáçîðå îáñóaeäàþòñÿ 4 îñíîâíûõ ìåõàíèçìà äåéñòâèÿ ðèòóêñèìàáà, ïðèâîäÿùèå ê ñíèaeåíèþ ïîïóëÿöèè Â-ëèìôîöèòîâ ó ïàöèåíòîâ ñ ëèìôîïðîëèôåðàòèâíûìè ïðîöåññàìè. … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2017

2023

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

(1 citation statement)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ритуксимаб -хи мерное моноклональное антитело к поверхностному антигену Влимфоцитов -CD20. Связывание ритук симаба с CD20 запускает иммунные реакции (компле ментзависимую цитотоксичность, антителозависимую цитотоксичность и апоптоз), приводящие в конечном итоге к лизису зрелых CD20 + Вклеток и, соответ ственно, к истощению пула Влимфоцитов / плазмати ческих клеток, продуцирующих аутоантитела про тив собственных эритроцитов [39]. Через 12 мес ответ на сочетанную терапию был значительно выше, чем при назначении ГКС в монорежиме: 75 % против 36 % (р = 0,003).…”

unclassified

Autoimmune hemolytic anemia: the current state of the issue

Vasilchenkova,

Galtseva,

Lukina

2023

Onkogematologiâ

View full text Add to dashboard Cite

Autoimmune hemolytic anemia is a rare disease characterized by the appearance of anti-erythrocyte autoantibodies and subsequent destruction of red blood cells by cells of the immune system. The destruction mechanisms of erythrocytes loaded with autoantibodies are well studied; however, the initial mechanisms that trigger the production of antibodies to own erythrocytes antigens remain unclear. In the pathogenesis of autoimmune hemolytic anemia, an important role is played by impaired immunological tolerance, in which T-lymphocytes play a key role. The study of T-lymphocytes subpopulation in patients with autoimmune hemolytic anemia by flow cytometry can provide valuable information for studying the disease pathogenesis and developing new approaches to its treatment.

show abstract

unclassified

Autoimmune hemolytic anemia: the current state of the issue

Vasilchenkova,

Galtseva,

Lukina

2023

Onkogematologiâ

View full text Add to dashboard Cite

show abstract

Biological Therapeutic Treatment of Atopic Dermatitis

Кубанова

Кубанов

Карамова

et al. 2017

Vestnik dermatologii i venerologii

View full text Add to dashboard Cite

Atopic dermatitis is a chronic recurrent inflammatory disease caused, inter alia, by violations of the barrier function of the skin and pathological immune response in the form of an imbalance of Th1 and Th2 lymphocytes with increased production of IL-4, IL-5, IL-13, IL-31. Treatment of severe forms of atopic dermatitis is not an easy task due to the variability of the individual response to treatment, the short duration of the therapeutic effect and the frequent development of undesirable phenomena associated with the use of existing methods of systemic immunosuppressive therapy. The study of the pathogenesis of atopic dermatitis made it possible to identify the spectrum of molecular targets, providing the basis for researching alternative variants to the previously used systemic therapy methods – genetic engineering biological preparations. Contemporary data on the pathogenesis of atopic dermatitis as well as potential molecular targets for innovative biological preparations, the efficacy of which has been evaluated through clinical trials, are presented in the review.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Механизмы Действия Ритуксимаба

Cited by 2 publications

References 24 publications

Autoimmune hemolytic anemia: the current state of the issue

Autoimmune hemolytic anemia: the current state of the issue

Biological Therapeutic Treatment of Atopic Dermatitis

Contact Info

Product

Resources

About